{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:34:01Z","timestamp":1789706041180,"version":"4.0.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-025-10549-4","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:48:04Z","timestamp":1755823684000},"page":"1291-1305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hyperkalemia in Heart Failure with Reduced Ejection Fraction: Implications and Management"],"prefix":"10.1007","volume":"30","author":[{"given":"Craig J.","family":"Beavers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"issue":"6","key":"10549_CR1","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.2215\/CJN.08580813","volume":"10","author":"BF Palmer","year":"2015","unstructured":"Palmer BF (2015) Regulation of potassium homeostasis. Clin J Am Soc Nephrol 10(6):1050\u20131060","journal-title":"Clin J Am Soc Nephrol"},{"key":"10549_CR2","doi-asserted-by":"crossref","unstructured":"Fisch C, Knoebel SB, Feigenbaum H, nspan K (1966) Potassium and the monophasic action potential, electrocardiogram, conduction and arrhythmias. Progr Cardiovasc Diseas 8(5):387\u2013418","DOI":"10.1016\/S0033-0620(66)80029-4"},{"key":"10549_CR3","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1093\/eurheartj\/ehx460","volume":"38","author":"M Aldahl","year":"2017","unstructured":"Aldahl M, Jensen AC, Davidsen L, Eriksen MA, M\u00f8ller HS, Nielsen BJ, Krogager ML, K\u00f8ber L, Torp-Pedersen C, S\u00f8gaard P (2017) Associations of serum potassium levels with mortality in chronic heart failure patients. Eur Heart J 38:2890\u20132896. https:\/\/doi.org\/10.1093\/eurheartj\/ehx460","journal-title":"Eur Heart J"},{"key":"10549_CR4","doi-asserted-by":"publisher","unstructured":"Jain N, Kotla S, Little BB, Weideman RA, Brilakis ES, Reilly RF, Banerjee S (2012) Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol 109(10):1510\u20133. https:\/\/doi.org\/10.1016\/j.amjcard.2012.01.367","DOI":"10.1016\/j.amjcard.2012.01.367"},{"key":"10549_CR5","doi-asserted-by":"publisher","unstructured":"Krogager ML, Torp-Pedersen C, Mortensen RN, K\u00f8ber L, Gislason G, S\u00f8gaard P, Aasbjerg K (2017) Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data. Eur Heart J 38(2):104\u2013112. https:\/\/doi.org\/10.1093\/eurheartj\/ehw129","DOI":"10.1093\/eurheartj\/ehw129"},{"key":"10549_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3909\/ricm0727","volume":"15","author":"PA McCullough","year":"2014","unstructured":"McCullough PA, Beaver TM, Bennett-Guerrero E, Emmett M, Fonarow GC, Goyal A, Herzog CA, Kosiborod M, Palmer BF (2014) Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management. Rev Cardiovasc Med 15:11\u201323. https:\/\/doi.org\/10.3909\/ricm0727","journal-title":"Rev Cardiovasc Med"},{"key":"10549_CR7","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1161\/CIRCULATIONAHA.117.030576","volume":"137","author":"J N\u00fa\u00f1ez","year":"2018","unstructured":"N\u00fa\u00f1ez J, Bay\u00e9s-Gen\u00eds A, Zannad F, Rossignol P, N\u00fa\u00f1ez E, Bod\u00ed V, Mi\u00f1ana G, Santas E, Chorro FJ, Mollar A et al (2018) Long-term potassium monitoring and dynamics in heart failure and risk of mortality. Circulation 137:1320\u20131330. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030576","journal-title":"Circulation"},{"key":"10549_CR8","unstructured":"Chisholm-Burns MA, Schwinghammer TL, Malone PM, Kolesar JM, Bradon Bookstaver P, Lee KC (2022) Pharmacotherapy Principles and Practice.\u00a06th ed. Volume 1. McGraw Hill; New York, NY, USA. Chapter 28: fluids and Electrolytes; pp. 479\u2013492"},{"key":"10549_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.rce.2018.01.006","volume":"218","author":"\u00c1 Hern\u00e1ez","year":"2018","unstructured":"Hern\u00e1ez \u00c1, Delgado JF, Cinca J, Fern\u00e1ndez-Avil\u00e9s F, Marrugat J (2018) Prevalence and incidence of hyperkalaemia in the Spanish population with heart failure with reduced ejection fraction: a systematic review and populational relevance. Rev Clin Esp (Barc) 218:253\u2013260. https:\/\/doi.org\/10.1016\/j.rce.2018.01.006","journal-title":"Rev Clin Esp (Barc)"},{"key":"10549_CR10","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.jacc.2016.06.060","volume":"68","author":"CM Sarwar","year":"2016","unstructured":"Sarwar CM, Papadimitriou L, Pitt B, Pi\u00f1a I, Zannad F, Anker SD, Gheorghiade M, Butler J (2016) Hyperkalemia in heart failure. J Am Coll Cardiol 68:1575\u20131589. https:\/\/doi.org\/10.1016\/j.jacc.2016.06.060","journal-title":"J Am Coll Cardiol"},{"key":"10549_CR11","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s11897-009-0037-1","volume":"6","author":"AS Desai","year":"2009","unstructured":"Desai AS (2009) Hyperkalemia in patients with heart failure: incidence, prevalence, and management. Curr Heart Fail Rep 6:272\u2013280. https:\/\/doi.org\/10.1007\/s11897-009-0037-1","journal-title":"Curr Heart Fail Rep"},{"key":"10549_CR12","doi-asserted-by":"publisher","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Henderson AD, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J, Chang-Sheng M, Chiang CE, Chioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland S, Goncalvesova E, Kang S, Katova T, Kosiborod MN, Latkovskis G, Lee AP, Linssen GCM, Llamas-Esper\u00f3n G, Mareev V, Martinez FA, Melenovsk\u00fd V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov L, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Kolkhof P, Viswanathan P; FINEARTS-HF Committees and Investigators (2024) Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2407107.","DOI":"10.1056\/NEJMoa2407107"},{"issue":"6","key":"10549_CR13","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL, FIDELIO-DKD and FIGARO-DKD investigators (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the fidelity pooled analysis. Eur Heart J 43(6):474\u2013484. https:\/\/doi.org\/10.1093\/eurheartj\/ehab777","journal-title":"Eur Heart J"},{"key":"10549_CR14","doi-asserted-by":"publisher","unstructured":"Filippatos G, Anker SD, B\u00f6hm M, Gheorghiade M, K\u00f8ber L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Kim SY, Nowack C, Palombo G, Kolkhof P, Kimmeskamp-Kirschbaum N, Pieper A, Pitt B (2016) A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J. 37(27):2105\u201314. https:\/\/doi.org\/10.1093\/eurheartj\/ehw132","DOI":"10.1093\/eurheartj\/ehw132"},{"issue":"1","key":"10549_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jamacardio.2024.4539","volume":"10","author":"O Vardeny","year":"2025","unstructured":"Vardeny O, Vaduganathan M, Claggett BL et al (2025) Finerenone, serum potassium, and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction. JAMA Cardiol 10(1):42\u201348. https:\/\/doi.org\/10.1001\/jamacardio.2024.4539","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10549_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","volume":"33","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Joseph A, Anker SD et al (2022) Hyperkalemia risk with Finerenone: results from the FIDELIO-DKD trial. J Am Soc Nephrol 33(1):225\u2013237","journal-title":"J Am Soc Nephrol"},{"key":"10549_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105573","volume":"169","author":"J Bao","year":"2021","unstructured":"Bao J, Kan R, Chen J, Xuan H, Wang C, Li D, Xu T (2021) Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction: a systematic review and network meta-analysis of randomized clinical trials. Pharmacol Res 169:105573. https:\/\/doi.org\/10.1016\/j.phrs.2021.105573","journal-title":"Pharmacol Res"},{"key":"10549_CR18","doi-asserted-by":"publisher","unstructured":"Crespo-Leiro MG, Barge-Caballero E, Segovia-Cubero J, Gonz\u00e1lez-Costello J, L\u00f3pez-Fern\u00e1ndez S, Garc\u00eda-Pinilla JM, Almenar-Bonet L, de Juan-Bagud\u00e1 J, Roig-Minguell E, Bay\u00e9s-Gen\u00eds A et al. (2020) Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry.\u00a0Rev. Esp. Cardiol. (Engl. Ed.); 73:313\u2013323. https:\/\/doi.org\/10.1016\/j.recesp.2019.05.004","DOI":"10.1016\/j.recesp.2019.05.004"},{"key":"10549_CR19","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","volume":"374","author":"MA Konstam","year":"2009","unstructured":"Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S et al (2009) Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374:1840\u20131848. https:\/\/doi.org\/10.1016\/S0140-6736(09)61913-9","journal-title":"Lancet"},{"key":"10549_CR20","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","volume":"100","author":"M Packer","year":"1999","unstructured":"Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryd\u00e9n L, Thygesen K, Uretsky BF (1999) Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure ATLAS Study Group. Circulation 100:2312\u20132318. https:\/\/doi.org\/10.1161\/01.CIR.100.23.2312","journal-title":"Circulation"},{"key":"10549_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jacc.2003.06.021","volume":"43","author":"JE Macdonald","year":"2004","unstructured":"Macdonald JE, Struthers AD (2004) What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol 43:155\u2013161. https:\/\/doi.org\/10.1016\/j.jacc.2003.06.021","journal-title":"J Am Coll Cardiol"},{"key":"10549_CR22","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ijcard.2009.04.041","volume":"144","author":"MI Ahmed","year":"2010","unstructured":"Ahmed MI, Ekundayo OJ, Mujib M, Campbell RC, Sanders PW, Pitt B, Perry GJ, Bakris G, Aban I, Love TE et al (2010) Mild hyperkalemia and outcomes in chronic heart failure: a propensity matched study. Int J Cardiol 144:383\u2013388. https:\/\/doi.org\/10.1016\/j.ijcard.2009.04.041","journal-title":"Int J Cardiol"},{"key":"10549_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ijcard.2011.06.121","volume":"158","author":"A Bielecka-Dabrowa","year":"2012","unstructured":"Bielecka-Dabrowa A, Mikhailidis DP, Jones L, Rysz J, Aronow WS, Banach M (2012) The meaning of hypokalemia in heart failure. Int J Cardiol 158:12\u201317. https:\/\/doi.org\/10.1016\/j.ijcard.2011.06.121","journal-title":"Int J Cardiol"},{"key":"10549_CR24","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1161\/CIRCHEARTFAILURE.109.899526","volume":"3","author":"CB Bowling","year":"2010","unstructured":"Bowling CB, Pitt B, Ahmed MI, Aban IB, Sanders PW, Mujib M, Campbell RC, Love TE, Aronow WS, Allman RM et al (2010) Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease. Circ Heart Fail 3:253\u2013260. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.109.899526","journal-title":"Circ Heart Fail"},{"key":"10549_CR25","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1016\/j.amjcard.2016.08.078","volume":"118","author":"S Hoss","year":"2016","unstructured":"Hoss S, Elizur Y, Luria D, Keren A, Lotan C, Gotsman I (2016) Serum potassium levels and outcome in patients with chronic heart failure. Am J Cardiol 118:1868\u20131874. https:\/\/doi.org\/10.1016\/j.amjcard.2016.08.078","journal-title":"Am J Cardiol"},{"issue":"4","key":"10549_CR26","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1152\/advan.00121.2016","volume":"40","author":"BF Palmer","year":"2016","unstructured":"Palmer BF, Clegg DJ (2016) Physiology and pathophysiology of potassium homeostasis. Adv Physiol Educ 40(4):480\u2013490","journal-title":"Adv Physiol Educ"},{"key":"10549_CR27","unstructured":"Food and Nutrition Board. Institute of Medicine. Potassium. DietaryReference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate.Washington, DC: National Academies Press, 2005, p. 186 \u2013268"},{"key":"10549_CR28","unstructured":"USDA\/Agricultural Research Service. Nutrient intakes from food. Meanamounts consumed per individual, by gender and age. What we eat inAmerica, NHANES 2007\u20132008 (Online). http:\/\/www.ars.usda.gov\/ba\/bhnrc\/fsrg [Updated 14 April 2011]"},{"key":"10549_CR29","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1001\/jama.2015.18396","volume":"315","author":"KB DeSalvo","year":"2016","unstructured":"DeSalvo KB, Olson R, Casavale KO (2016) Dietary guidelines for Americans. JAMA 315:457\u2013458. https:\/\/doi.org\/10.1001\/jama.2015.18396","journal-title":"JAMA"},{"key":"10549_CR30","first-page":"165","volume":"12","author":"RJ Hen\u00e9","year":"1986","unstructured":"Hen\u00e9 RJ, Koomans HA, Boer P, Dorhout Mees EJ (1986) Adaptation tochronic potassium loading in normal man. Miner Electrolyte Metab 12:165\u2013172","journal-title":"Miner Electrolyte Metab"},{"key":"10549_CR31","doi-asserted-by":"publisher","first-page":"F541","DOI":"10.1152\/ajprenal.00427.2006","volume":"293","author":"FN Lee","year":"2007","unstructured":"Lee FN, Oh G, McDonough AA, Youn JH (2007) Evidence for gut factor in K homeostasis. Am J Physiol Renal Physiol 293:F541\u2013F547. https:\/\/doi.org\/10.1152\/ajprenal.00427.2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10549_CR32","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.semneph-rol.2013.04.005","volume":"33","author":"JH Youn","year":"2013","unstructured":"Youn JH (2013) Gut sensing of potassium intake and its role in potassium homeostasis. Semin Nephrol 33:248\u2013256. https:\/\/doi.org\/10.1016\/j.semneph-rol.2013.04.005","journal-title":"Semin Nephrol"},{"key":"10549_CR33","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/ki.1990.295","volume":"38","author":"TJ Rabelink","year":"1990","unstructured":"Rabelink TJ, Koomans HA, Hen\u00e9 RJ, Dorhout Mees EJ (1990) Early and lateadjustment to potassium loading in humans. Kidney Int 38:942\u2013947. https:\/\/doi.org\/10.1038\/ki.1990.295","journal-title":"Kidney Int"},{"key":"10549_CR34","doi-asserted-by":"publisher","first-page":"R421","DOI":"10.1152\/ajpregu.00095.2011","volume":"301","author":"KS Oh","year":"2011","unstructured":"Oh KS, Oh YT, Kim SW, Kita T, Kang I, Youn JH (2011) Gut sensing of dietary K intake increases renal kexcretion. Am J Physiol Regul Integr Comp Physiol 301:R421\u2013R429. https:\/\/doi.org\/10.1152\/ajpregu.00095.2011","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10549_CR35","doi-asserted-by":"publisher","first-page":"F663","DOI":"10.1152\/ajpre-nal.00514.2005","volume":"291","author":"T Morimoto","year":"2006","unstructured":"Morimoto T, Liu W, Woda C, Carattino MD, Wei Y, Hughey RP, Apodaca G, Satlin LM, Kleyman TR (2006) Mechanism underlying flowstimulation of sodium absorption in the mammalian collecting duct. Am JPhysiol Renal Physiol 291:F663\u2013F669. https:\/\/doi.org\/10.1152\/ajpre-nal.00514.2005","journal-title":"Am JPhysiol Renal Physiol"},{"key":"10549_CR36","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.2215\/CJN.08580813","volume":"10","author":"BF Palmer","year":"2015","unstructured":"Palmer BF (2015) Regulation of potassium homeostasis. Clin J Am Soc Nephrol 10:1050\u20131060. https:\/\/doi.org\/10.2215\/CJN.08580813","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10549_CR37","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1681\/ASN.2011040414","volume":"22","author":"PS Aronson","year":"2011","unstructured":"Aronson PS, Giebisch G (2011) Effects of pH on potassium: new explanations for old observations. J Am Soc Nephrol 22(11):1981\u20131989. https:\/\/doi.org\/10.1681\/ASN.2011040414","journal-title":"J Am Soc Nephrol"},{"key":"10549_CR38","doi-asserted-by":"publisher","unstructured":"A Cornelius RJ, Wen D, Hatcher LI, Sansom SC (2012) Bicarbonate promotes BK-\/4-mediated K excretion in the renal distal nephron. Am J Physiol Renal Physiol 303: F1563\u2013F1571. https:\/\/doi.org\/10.1152\/ajprenal.00490.2012","DOI":"10.1152\/ajprenal.00490.2012"},{"key":"10549_CR39","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.semneph-rol.2013.04.003","volume":"33","author":"ML Gumz","year":"2013","unstructured":"Gumz ML, Rabinowitz L (2013) Role of circadian rhythms in potassium homeostasis. Semin Nephrol 33:229\u2013236. https:\/\/doi.org\/10.1016\/j.semneph-rol.2013.04.003","journal-title":"Semin Nephrol"},{"issue":"8","key":"10549_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13551","volume":"51","author":"AP Maggioni","year":"2021","unstructured":"Maggioni AP, Dondi L, Andreotti F, Calabria S, Iacoviello M, Gorini M, Gonzini L, Piccinni C, Ronconi G, Martini N (2021) Prevalence, clinical impact and costs of hyperkalaemia: special focus on heart failure. Eur J Clin Invest 51(8):e13551","journal-title":"Eur J Clin Invest"},{"issue":"4","key":"10549_CR41","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1002\/ehf2.14661","volume":"11","author":"DE Grobbee","year":"2024","unstructured":"Grobbee DE, Filippatos G, Desai NR, Coats AJS, Pinto F, Rosano GMC, Cleland JGF, Kammerer J, de Arellano AR (2024) Epidemiology and risk factors for hyperkalaemia in heart failure. ESC Heart Fail 11(4):1821\u20131840. https:\/\/doi.org\/10.1002\/ehf2.14661","journal-title":"ESC Heart Fail"},{"issue":"8","key":"10549_CR42","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1080\/03007995.2020.1775072","volume":"36","author":"F Mu","year":"2020","unstructured":"Mu F, Betts KA, Woolley JM, Dua A, Wang Y, Zhong J, Wu EQ (2020) Prevalence and economic burden of hyperkalemia in the United States Medicare population. Curr Med Res Opin 36(8):1333\u20131341. https:\/\/doi.org\/10.1080\/03007995.2020.1775072","journal-title":"Curr Med Res Opin"},{"key":"10549_CR43","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S253745","author":"S Jim\u00e9nez-Marrero","year":"2020","unstructured":"Jim\u00e9nez-Marrero S, Cainzos-Achirica M, Monterde D, Garcia-Eroles L, Enjuanes C, Yun S, Garay A, Moliner P, Alcoberro L, Corbella X, Comin-Colet J (2020) Real-world epidemiology of potassium derangements among chronic cardiovascular, metabolic and renal conditions: a population-based analysis. Clin Epidemiol. https:\/\/doi.org\/10.2147\/CLEP.S253745","journal-title":"Clin Epidemiol"},{"key":"10549_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219899","volume":"14","author":"K Matsushita","year":"2019","unstructured":"Matsushita K, Sang Y, Yang C, Ballew SH, Grams ME, Coresh J et al (2019) Dyskalemia, its patterns, and prognosis among patients with incident heart failure: A nationwide study of US veterans. PLoS One 14:e0219899. https:\/\/doi.org\/10.1371\/journal.pone.0219899","journal-title":"PLoS One"},{"key":"10549_CR45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ijcard.2017.07.035","volume":"245","author":"E Nilsson","year":"2017","unstructured":"Nilsson E, Gasparini A, \u00c4rnl\u00f6v J, Xu H, Henriksson KM, Coresh J, Grams ME, Carrero JJ (2017) Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system. Int J Cardiol 245:277\u2013284","journal-title":"Int J Cardiol"},{"key":"10549_CR46","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/ehf2.12402","volume":"6","author":"C Linde","year":"2019","unstructured":"Linde C, Qin L, Bakhai A, Furuland H, Evans M, Ayoubkhani D et al (2019) Serum potassium and clinical outcomes in heart failure patients: Results of risk calculations in 21 334 patients in the UK. ESC Heart Fail 6:280\u2013290. https:\/\/doi.org\/10.1002\/ehf2.12402","journal-title":"ESC Heart Fail"},{"key":"10549_CR47","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/ckj\/sfab225","volume":"15","author":"G James","year":"2022","unstructured":"James G, Kim J, Mellstr\u00f6m C, Ford KL, Jenkins NC, Tsang C et al (2022) Serum potassium variability as a predictor of clinical outcomes in patients with cardiorenal disease or diabetes: a retrospective UK database study. Clin Kidney J 15:758\u2013770. https:\/\/doi.org\/10.1093\/ckj\/sfab225","journal-title":"Clin Kidney J"},{"key":"10549_CR48","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","volume":"72","author":"SJ Greene","year":"2018","unstructured":"Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI et al (2018) Medical therapy for heart failure with reduced ejection fraction: The CHAMP-HF registry. J Am Coll Cardiol 72:351\u2013366. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.070","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10549_CR49","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ejhf.1199","volume":"20","author":"M Trevisan","year":"2018","unstructured":"Trevisan M, de Deco P, Xu H et al (2018) Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail 20(8):1217\u20131226. https:\/\/doi.org\/10.1002\/ejhf.1199","journal-title":"Eur J Heart Fail"},{"key":"10549_CR50","doi-asserted-by":"crossref","unstructured":"Pitt B, Zannad F, Remme WJ, Randomized Aldactone Evaluation Study Investigators et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341:709\u2013717","DOI":"10.1056\/NEJM199909023411001"},{"key":"10549_CR51","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","volume":"7","author":"P Rossignol","year":"2014","unstructured":"Rossignol P, Dobre D, McMurray JJ et al (2014) Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 7:51\u201358","journal-title":"Circ Heart Fail"},{"key":"10549_CR52","doi-asserted-by":"publisher","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW (2022) AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-e1032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063. Epub 2022 Apr 1. Erratum in: Circulation. 2022 May 3;145(18):e1033. https:\/\/doi.org\/10.1161\/CIR.0000000000001073. Erratum in: Circulation. 2022 Sep 27;146(13):e185. https:\/\/doi.org\/10.1161\/CIR.0000000000001097. Erratum in: Circulation. 2023 Apr 4;147(14):e674. https:\/\/doi.org\/10.1161\/CIR.0000000000001142","DOI":"10.1161\/CIR.0000000000001063"},{"key":"10549_CR53","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/ejhf.1079","volume":"20","author":"JC Beusekamp","year":"2018","unstructured":"Beusekamp JC, Tromp J, van der Wal HH, Anker SD, Cleland JG, Dickstein K et al (2018) Potassium and the use of renin\u2013angiotensin\u2013aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF. Eur J Heart Fail 20:923\u2013930. https:\/\/doi.org\/10.1002\/ejhf.1079","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10549_CR54","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004A) Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 351(6):543\u2013551. https:\/\/doi.org\/10.1056\/NEJMoa040135","journal-title":"N Engl J Med"},{"issue":"9","key":"10549_CR55","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.repc.2020.03.015","volume":"39","author":"C Fonseca","year":"2020","unstructured":"Fonseca C, Brito D, Branco P, Fraz\u00e3o JM, Silva-Cardoso J, Bettencourt P (2020) Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: a systematic review. Rev Port Cardiol (Engl Ed) 39(9):517\u2013541. https:\/\/doi.org\/10.1016\/j.repc.2020.03.015","journal-title":"Rev Port Cardiol (Engl Ed)"},{"issue":"6","key":"10549_CR56","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.cardfail.2022.01.012","volume":"28","author":"RJ Desai","year":"2022","unstructured":"Desai RJ, Solomon SD, Vaduganathan M (2022) Rates of spironolactone initiation and subsequent hyperkalemia hospitalizations in patients with heart failure with preserved ejection fraction following the TOPCAT trial: a cohort study of medicare beneficiaries. J Card Fail 28(6):1035\u20131039. https:\/\/doi.org\/10.1016\/j.cardfail.2022.01.012","journal-title":"J Card Fail"},{"issue":"2","key":"10549_CR57","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.amjcard.2016.09.038","volume":"119","author":"J Tromp","year":"2017","unstructured":"Tromp J et al (2017) The impact of hyperkalemia on clinical outcomes in heart failure patients: a detailed analysis of risk factors and treatment implications. Am J Cardiol 119(2):290\u2013296","journal-title":"Am J Cardiol"},{"issue":"3","key":"10549_CR58","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000479802","volume":"46","author":"AJ Collins","year":"2017","unstructured":"Collins AJ, Pitt B, Reaven N, Funk S, McGaughey K, Wilson D, Bushinsky D (2017) Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and diabetes. Am J Nephrol 46(3):213\u2013221","journal-title":"Am J Nephrol"},{"issue":"9","key":"10549_CR59","first-page":"e007485","volume":"13","author":"WF Peacock","year":"2020","unstructured":"Peacock WF, Chandra A, Char D, Ding D, Young M, Callahan M (2020) Evaluation of hyperkalemia in patients with cardiovascular disease: a narrative review. Circ Heart Fail 13(9):e007485","journal-title":"Circ Heart Fail"},{"issue":"4","key":"10549_CR60","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/ehjcvp\/pvv026","volume":"1","author":"ML Krogager","year":"2015","unstructured":"Krogager ML, Torp-Pedersen C, Mortensen RN et al (2015) Short-term mortality risk of serum potassium levels in acute heart failure following myocardial infarction. Eur Heart J Cardiovasc Pharmacother 1(4):245\u2013251","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10549_CR61","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/ehjqcco\/qcy019","volume":"4","author":"E Nilsson","year":"2018","unstructured":"Nilsson E, de Peco P, Trevisan M et al (2018) A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failure. Eur Heart J Qual Care Clin Outcomes 4:267\u2013273","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"24","key":"10549_CR62","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1161\/01.CIR.0000132482.95686.87","volume":"109","author":"M Gheorghiade","year":"2004","unstructured":"Gheorghiade M, Adams KF Jr, Colucci WS (2004) Digoxin in the management of cardiovascular disorders. Circulation 109(24):2959\u20132964","journal-title":"Circulation"},{"issue":"2","key":"10549_CR63","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1001\/jama.2011.1967","volume":"307","author":"A Goyal","year":"2012","unstructured":"Goyal A, Spertus JA, Gosch K et al (2012) Serum potassium levels and mortality in acute myocardial infarction. JAMA 307(2):157\u2013164. https:\/\/doi.org\/10.1001\/jama.2011.1967","journal-title":"JAMA"},{"issue":"4","key":"10549_CR64","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/phar.1907","volume":"37","author":"KA Alburikan","year":"2017","unstructured":"Alburikan KA, Galoosian A, Aljamal MS (2017) Impact of pharmacist interventions on the use of renin-angiotensin-aldosterone system inhibitors in patients with heart failure: a systematic review and meta-analysis. Pharmacotherapy 37(4):469\u2013478. https:\/\/doi.org\/10.1002\/phar.1907","journal-title":"Pharmacotherapy"},{"issue":"22","key":"10549_CR65","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1056\/NEJMsa1107913","volume":"365","author":"NK Choudhry","year":"2011","unstructured":"Choudhry NK, Avorn J, Glynn RJ et al (2011) Full coverage for preventive medications after myocardial infarction. N Engl J Med 365(22):2088\u20132097. https:\/\/doi.org\/10.1056\/NEJMsa1107913","journal-title":"N Engl J Med"},{"issue":"5","key":"10549_CR66","first-page":"667","volume":"70","author":"CP Kovesdy","year":"2017","unstructured":"Kovesdy CP et al (2017) Management of hyperkalemia in chronic kidney disease: a nephrology perspective. Am J Kidney Dis 70(5):667\u2013676","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10549_CR67","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1053\/j.ajkd.2010.03.022","volume":"56","author":"N Noori","year":"2010","unstructured":"Noori N et al (2010) Dietary potassium intake and mortality in long-term hemodialysis patients. Am J Kidney Dis 56(2):338\u2013347","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10549_CR68","doi-asserted-by":"crossref","first-page":"908","DOI":"10.2215\/CJN.16871020","volume":"16","author":"K Kalantar-Zadeh","year":"2021","unstructured":"Kalantar-Zadeh K et al (2021) Nutritional management of hyperkalemia: the case for a plant-rich diet. Clin J Am Soc Nephrol 16(6):908\u2013910","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10549_CR69","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1681\/ASN.2020030384","volume":"32","author":"J Kelly","year":"2021","unstructured":"Kelly J, Su G, Zhang L, Qin X, Marshall S, Gonz\u00e1lez-Ortiz A, Clase C, Campbell K, Xu H, Carrero J-J (2021) Modifiable lifestyle factors for primary prevention of CKD: a systematic review and meta-analysis. JASN 32(1):239\u2013253. https:\/\/doi.org\/10.1681\/ASN.2020030384","journal-title":"JASN"},{"key":"10549_CR70","doi-asserted-by":"publisher","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R; FLOW trial committees and investigators. effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024 Jul 11;391(2):109\u2013121. https:\/\/doi.org\/10.1056\/NEJMoa2403347","DOI":"10.1056\/NEJMoa2403347"},{"issue":"3","key":"10549_CR71","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.kint.2023.11.025","volume":"105","author":"EL Fu","year":"2024","unstructured":"Fu EL, Mastrorilli J, Bykov K, Wexler DJ, Cervone A, Lin KJ, Patorno E, Paik JM (2024) A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes. Kidney Int 105(3):618\u2013628. https:\/\/doi.org\/10.1016\/j.kint.2023.11.025","journal-title":"Kidney Int"},{"issue":"24","key":"10549_CR72","first-page":"2348","volume":"41","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI (2020) Sodium\u2013glucose cotransporter 2 inhibitors and risk of hyperkalemia in patients with type 2 diabetes: a systematic review and meta-analysis. Eur Heart J 41(24):2348\u20132356","journal-title":"Eur Heart J"},{"issue":"19","key":"10549_CR73","first-page":"1894","volume":"42","author":"PS Jhund","year":"2021","unstructured":"Jhund PS, Greene SJ, Vaduganathan M et al (2021) Dapagliflozin and risk of hyperkalemia in patients with heart failure and reduced ejection fraction: results from DAPA-HF. Eur Heart J 42(19):1894\u20131901","journal-title":"Eur Heart J"},{"issue":"29","key":"10549_CR74","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1093\/eurheartj\/ehac306","volume":"43","author":"JP Ferreira","year":"2022","unstructured":"Ferreira JP, Zannad F, Butler J et al (2022) Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled. Eur Heart J 43(29):2984\u20132993","journal-title":"Eur Heart J"},{"issue":"5","key":"10549_CR75","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/ejhf.1811","volume":"22","author":"AS Desai","year":"2020","unstructured":"Desai AS, Vardeny O, Claggett B et al (2020) Effect of sacubitril\u2013valsartan vs enalapril on serum potassium in patients with heart failure and reduced ejection fraction: The PARADIGM-HF trial. Eur J Heart Fail 22(5):821\u2013828","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10549_CR76","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"PE Stevens","year":"2013","unstructured":"Stevens PE, Levin A (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158(11):825\u2013830","journal-title":"Ann Intern Med"},{"key":"10549_CR77","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Filippatos G, Pitt B et al (2021) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43:474\u2013484","journal-title":"Eur Heart J"},{"issue":"10333","key":"10549_CR78","first-page":"2223","volume":"399","author":"B Pitt","year":"2022","unstructured":"Pitt B, Bakris GL, Bushinsky DA et al (2022) Patiromer for the management of hyperkalemia in patients receiving RAAS inhibitors in heart failure: DIAMOND trial results. Lancet 399(10333):2223\u20132235","journal-title":"Lancet"},{"issue":"3","key":"10549_CR79","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"MR Weir","year":"2015","unstructured":"Weir MR, Bakris GL, Bushinsky DA et al (2015) Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 372(3):211\u2013221","journal-title":"N Engl J Med"},{"issue":"21","key":"10549_CR80","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1001\/jama.2014.15688","volume":"312","author":"M Kosiborod","year":"2014","unstructured":"Kosiborod M, Rasmussen HS, Lavin PT et al (2014) Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia. JAMA 312(21):2223\u20132233","journal-title":"JAMA"},{"issue":"6","key":"10549_CR81","first-page":"619","volume":"75","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ et al (2020) Sodium zirconium cyclosilicate for hyperkalemia in patients with heart failure. J Am Coll Cardiol 75(6):619\u2013630","journal-title":"J Am Coll Cardiol"},{"key":"10549_CR82","doi-asserted-by":"publisher","unstructured":"Kosiborod MN, Cherney D, Connelly K, Desai AS, Guimar\u00e3es PO, Kuthi L, Lala A, Madrini V Jr, Merkely B, Villota JN, Squire I, Testani JM, Vaclavik J, Verma S, Wranicz J, Dahl M, Eudicone JM, Friberg L, Petrie MC (2024Oct) Sodium zirconium cyclosilicate in HFrEF and hyperkalemia: realize-k design and baseline characteristics. JACC Heart Fail 12(10):1707\u20131716. https:\/\/doi.org\/10.1016\/j.jchf.2024.05.003","DOI":"10.1016\/j.jchf.2024.05.003"},{"issue":"15","key":"10549_CR83","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1007\/s10741-026-10597-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000}}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10549-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-025-10549-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10549-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T07:10:18Z","timestamp":1772089818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-025-10549-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":83,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10549"],"URL":"https:\/\/doi.org\/10.1007\/s10741-025-10549-4","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"26 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10741-026-10597-4","URL":"https:\/\/doi.org\/10.1007\/s10741-026-10597-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}